On June 9th 2017, the research integrity news website Retraction Watch brought an article titled: „Journal won’t look at allegations about papers more than six years old, nor from “public websites””. A public outcry followed, protesting about what was perceived an outrageous case of editorial cover-up of research fraud. The journal in question was Molecular & Cellular Biology (MCB), published by the American Society for Microbiology (ASM); the vituperative Retraction Watch article was prompted by an editorial in the June issue of this journal. The problem with that name-and-shame Retraction Watch article however was: the accusatory title did not fit their own main text at all, which did actually clarify that evidence on public websites like PubPeer is in fact very much looked at by the MCB journal editors, just not publicly commented upon. And that:
“The ASM spokesperson explained that, like the ORI, ASM journals will make exceptions to the six-year statute of limitations, for instance if older papers “provide evidence of an extensive pattern of misconduct.””
Continue reading “Journal announces to clean up past literature, gets “smeared” by Retraction Watch”
This article lists all known (including those not officially declared) patients of the scandal surgeon Paolo Macchiarini, who received from his a cadaveric or plastic trachea. All received grafts “regenerated” with bone marrow and epithelial cells, in some cases bioreactor was used to incubate cells on the trachea carcass, in some cases a “bionic” method was applied, where cells were brought straight into open patient, together with growth factors like EPO. Not all patients are named in my list, though names of all are available, certainly at the hospitals where they were treated. One of my sources is a patients list from the Careggi Hospital in Florence, Italy, which the Corriere Fiorentino journalist Alessio Gaggioli sent me. Some of the patients I already described in an earlier article.
This now is a full list, and it will be updated whenever I receive any new evidence. All Macchiarini trachea transplant patients are listed in the chronological order of their operation. The 2003 operated patient (story here), who received from Macchiarini (together with Heike and Thorsten Walles) a small “regenerated” tracheal patch of pig intestine, is not included here, as it was not a trachea transplant as such. There is a total of 17 patients, at least 11 are dead, the rest, if alive, were left mutilated.
Continue reading “Macchiarini’s trachea transplant patients: the full list”
Sonia Melo, the Portuguese cheater scientist and her former US-boss Raghu Kalluri issued some days ago a biorxive preprint, which sole purpose is to defend their discredited Nature paper from 2015. There, they originally claimed to have found a unique biomarker for early pancreatic cancer, a much hailed promise to save lives of many cancer patients. However, soon it was found out that the results were not reproducible, the Nature paper Melo et al, 2015 contained evidence of data manipulation (just like other Melo publications with Kalluri and her PhD boss Manel Esteller). The antibody, on which the central evidence for the allegedly unique pancreatic cancer biomarker glypican 1 (GPC1) was based, proved to be delivering staining artefacts; the vendor Thermo Scientific soon discontinued it. Even Kalluri seemingly distanced himself from his results.
Now in their new preprint, Melo and Kalluri claimed to have perfectly reproduced their original 2015 GPC1 results with a new antibody, which however proved to be likely exactly the same as the old one, but sold by a different vendor. As soon as this became known, the authors issued a new preprint version just two days later, featuring yet another entirely new GPC1 antibody, with an utterly new set of results to complement the 6 day older ones. However, also these results are most likely useless. The authors namely freely admit in their preprint method description to have intentionally manipulated their flow cytometry (FACS) data to obtain a positive signal specifically where needed. It seems that one full professor and three research group leaders have absolutely no understanding about data integrity in flow cytometry (or maybe even in research in general). Obviously, they simply adjust the FACS settings for each sample in an analytic row any way it pleases them until they see a result they like. As they don’t even hide it, they seem to think this is the proper way to do science. Continue reading “Melo and Kalluri defend discredited Nature paper with preprint, where they admit data “adjustments””
The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”
Arthur Caplan, internationally respected professor of bioethics and director of the Division of Medical Ethics at the New York University, requested publicly retractions of the bioethics reviews on regenerative medicine he co-authored with the scandal surgeon Paolo Macchiarini. Caplan notified the journals with his retraction requests, but said to have received no response from them yet. Not only this: Caplan calls for all works of Macchiarini to be retracted.
Macchiarini is now an international pariah, he recently again lost his job, this time with the Kazan Federal University in Russia (see my report). His publications are under investigation at his former workplace the Karolinska Institutet in Stockholm (where he was previously sacked), the Swedish state announced to soon charge him with manslaughter, due to 3 lethal plastic trachea transplants he performed at Karolinska. Continue reading “Bioethicist Arthur Caplan calls for retraction of all Macchiarini papers”
What did we learn from the trachea transplant scandal around the miracle surgeon and stem cell pioneer Paolo Macchiarini, who used to conduct his human experiments in Germany, Spain, Italy, Sweden and Russia? That despite the stem cell fairy magic, all his plastic trachea transplants proved deadly for his patients, except of one or two cases where the transplant was removed early enough. These patients were not saved by Macchiarini though: he quickly lost interest in his human Guinea pigs, especially when his miracle cures started to fail. One such patient, a young woman from Turkey, lost several organs in the process, and was only saved so far due to excellent medical care and organ transplants. Macchiarini meanwhile was busy experimenting on humans in Russia, the saddest case was that of another young woman who was tricked into agreeing to an allegedly life-improving plastic trachea, which caused her death soon after.
But it was not only about the lethal plastic, and there were more young women (and some men) who were killed or mutilated by Macchiarini’s trachea transplants, while other options were available to save their lives and health. What often remains unspoken: the technology which Macchiarini used before, that of a dead donor trachea stripped of cells and allegedly reconstituted with stem cells, failed as well. Without exception, but for some reason the method is still being presented as ground-breaking success and in fact there are currently clinical trials happening in UK and soon in the whole EU. These are led by none other than by Macchiarini’s formerly closest ally, the British surgeon Martin Birchall. What the two of them did to their very first patient whom they operated in 2008 at the Hospital Clinic Barcelona, is nothing less but a bankruptcy of basic medical ethics which almost costed that young woman her life. Other Spanish doctors have been rescuing her life ever since, while Macchiarini and Birchall were busy making their fame and careers by parading this utterly failed transplant of a rotting trachea as an epic success story.
The untold story of Claudia Castillo and her trachea transplant features these key points:
- Patient was neglected by Macchiarini and his Barcelona colleagues prior and after the transplant operation, while her condition deteriorated
- Standard therapies were not considered or rejected in favour of a totally untested, scientifically unfounded and unrealistic method
- “Informed constent” of the patient was obtained through deliberate misinformation
- The transplant was prepared in a British veterinary lab using animal products, in total disregard for elementary safety measures in human medicine. The responsible British authorities were misinformed, the incident soon covered up and all research documentation vanished.
Continue reading “Claudia’s trachea”
Five months ago, I reported about data integrity concerns in 6 publications authored by Min-Jean Yin, who had been working at the pharma giant Pfizer in La Jolla, California, as Senior Principal Scientist since 2003. One paper, where she contributed as a collaborator (Lamoureux et al, European Urology, 2014), has been corrected already in March 2016. Five other cancer research papers, on the efficiency of Pfizer’s own pharmacological enzyme inhibitors, will now be retracted, after an investigation performed by Pfizer confirmed the suspicions of data manipulation, originally raised on PubPeer. These five papers stemmed directly from the Pfizer lab which Yin used to be in charge of. Used to be – because according to her recently updated LinkedIn profile, Yin doesn’t work there anymore. Since September 2016, she joined a rather unremarkable Californian biotech start-up Diagnologix LLC in San Diego, as “General Manager”. With such a career (and surely also salary) setback, it is safe to assume Yin did not leave Pfizer after 13 years of service entirely voluntarily. Continue reading “5 retractions and a sack for Pfizer lead cancer researcher Min-Jean Yin”